Evaluation of spike protein antigens for SARS-CoV-2 serology

Jagtap, Suraj; Ratnasri, K; Valloly, Priyanka; Sharma, Renu; Maurya, Satyaghosh; Gaigore, Anushree; Ardhya, Chitra; Biligi, Dayananda S; Desiraju, Bapu Koundinya; Natchu, Uma Chandra Mouli; Saini, Deepak Kumar; Roy, Rahul

doi:10.1016/j.jviromet.2021.114222

Cited by 13 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The spike protein elicits the strongest humoral response upon infection (24)(25)(26)(27) and should be used as a reference in populationbased seroprevalence studies (28). Spike protein ectodomains were obtained from the National Research Council of Canada for the following strains: Wuhan-Hu-1 (PRO1-429 (SmT1-1), B.1.617.2 (PRO7176-1 [SmT1(B.1.617.2]), and P.1 (PRO6875-2 [SmT1v3-B]), where they were produced according to protocols reported elsewhere (29)(30)(31)(32).…”

Section: Sars-cov-2 Viral Antigensmentioning

confidence: 99%

Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance

et al. 2023

View full text Add to dashboard Cite

IntroductionEarly in the COVID-19 pandemic, reagent availability was not uniform, and infrastructure had to be urgently adapted to undertake COVID-19 surveillance.MethodsBefore the validation of centralized testing, two enzyme-linked immunosorbent assays (ELISA) were established independently at two decentralized sites using different reagents and instrumentation. We compared the results of these assays to assess the longitudinal humoral response of SARS-CoV-2-positive (i.e., PCR-confirmed), non-hospitalized individuals with mild to moderate symptoms, who had contracted SARSCoV-2 prior to the appearance of variants of concern in Québec, Canada.ResultsThe two assays exhibited a high degree of concordance to identify seropositive individuals, thus validating the robustness of the methods. The results also confirmed that serum immunoglobulins persist ≥ 6 months post-infection among non-hospitalized adults and that the antibodies elicited by infection cross-reacted with the antigens from P.1 (Gamma) and B.1.617.2 (Delta) variants of concern.DiscussionTogether, these results demonstrate that immune surveillance assays can be rapidly and reliably established when centralized testing is not available or not yet validated, allowing for robust immune surveillance.

show abstract

Section: Sars-cov-2 Viral Antigensmentioning

confidence: 99%

Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Many vaccines were developed for emergency use [ 2 ]. The vaccines could lead to the development of spike-specific IgG antibodies against SARS-CoV-2, so serology assays have been used to detect the spike protein domain antibodies induced by vaccination or prior viral exposure [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel

Romero-Ibarguengoitia

Rivera-Salinas

Hernández-Ruíz

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Background Vaccination is our main strategy to control SARS-CoV-2 infection. Given the decrease in quantitative SARS-CoV-2 spike 1–2 IgG antibody titers three months after the second BNT162b2 dose, healthcare workers received a third booster six months after completing the original protocol. This study aimed to analyze the quantitative SARS-CoV-2 spike 1–2 IgG antibody titers and the safety of the third dose. Material and methods A prospective longitudinal cohort study included healthcare workers who received a third booster six months after completing the BNT162b2 regimen. We assessed the quantitative SARS-CoV-2 spike 1–2 IgG antibody titers 21–28 days after the first and second dose, three months after the completed protocol, 1–7 days following the third dose, and 21–28 days after booster administration. Results The cohort comprised 168 participants aged 41(10) years old, 67% of whom were female. The third dose was associated with an increase in quantitative antibody titers, regardless of previous SARS-CoV-2 history. In cases with a negative SARS-CoV-2 history, the median (IQR) antibody titer values increased from 379 (645.4) to 2960 (2010) AU/ml, whereas in cases with a positive SARS-CoV-2 history, from 590 (1262) to 3090 (2080) AU/ml (p<0.001). The third dose caused a lower number of total (local and systemic) adverse events following immunization (AEFI) compared with the first two vaccines. However, in terms of specific symptoms such as fatigue, myalgia, arthralgia, fever, and adenopathy, the proportion was higher in comparison with the first and second doses (p<0.05). The most common AEFI after the third BNT162b2 vaccine was pain at the injection site (n = 82, 84.5%), followed by fatigue (n = 45, 46.4%) of mild severity (n = 36, 37.1%). Conclusion The third dose applied six months after the original BNT162b2 regimen increased the quantitative SARS-CoV-2 spike 1–2 IgG antibody titers. The booster dose was well tolerated and caused no severe AEFI.

show abstract

“…The objective of RT-PCR tests is to make a reagent react with the genetic code of the virus (RNA). The antigenic test focuses on the structural proteins of the virus, the spike protein (S), and the nucleocapsid protein (N) [45].…”

Section: Use Of Colloidal Gold During the Covid-19 Pandemicmentioning

confidence: 99%

Perspective Chapter: Gold Nanoparticles Market – A Global Overview and New Challenges in the Post-Pandemic Economy

Verny¹,

Oulmakki²,

Meza³

2023

Gold Nanoparticles and Their Applications in Engineering

View full text Add to dashboard Cite

Colloidal gold (AuNP) is a molecule obtained from pure gold (Au), and has several uses in the health, industrial, and chemical sectors. There are several processes to generate it and these methods are perfected over time. However, colloidal gold manufacturers and their customers are dependent on the pure gold market, its disruptions, and fluctuations. This paper first shows that the gold market is currently unstable due to the existing pandemic and geopolitical conflicts. The main gold producers, China, Russia, and Australia, together account for more than a quarter of the world’s gold production, and only a few European countries produce gold in small quantities. Europe is therefore forced to import gold, including colloidal gold. Several innovations related to gold nanoparticles are emerging, notably in the miniaturization of industrial components or in the health sector during the pandemic. The objective of this chapter is therefore to understand the patterns into which these countries must fit to produce these particles and the economic, political, and scientific stakeholders involved in capturing these flows. Through the prism of the gold market, the electronics industry, and the health field, this chapter looks at these issues while putting into perspective the salient facts that could impact this market in the years to come.

show abstract

Evaluation of spike protein antigens for SARS-CoV-2 serology

Cited by 13 publications

References 42 publications

Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance

Assessment of the longitudinal humoral response in non-hospitalized SARS-CoV-2-positive individuals at decentralized sites: Outcomes and concordance

Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel

Perspective Chapter: Gold Nanoparticles Market – A Global Overview and New Challenges in the Post-Pandemic Economy

Contact Info

Product

Resources

About